An Additional LDL-Lowering Effect of Amlodipine; Not Only an Antihypertensive?

References

• Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 8(334):374–381.
   Google Scholar
• Halperin R, Sesso H, Ma J, Buring J, Stampfer M, Gaziano J. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47(1):45–50.
   PubMed Web of Science ®Google Scholar
• Hokanson J, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2):213–219.
   PubMedGoogle Scholar
• Keane W, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33(5):1004–1010.
   PubMed Web of Science ®Google Scholar
• Ohta M, Tajiri Y, Yamato H, Ikeda M. Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. Clin Exp Hypertens 2012. doi:10.3109/10641963.2012.681722. [Epub ahead of print].
   Google Scholar
• Dimmitt S, Williams P, Croft K, Beilin L. Effects of beta-blockers on the concentration and oxidizability of plasma lipids. Clin Sci (Lond) 1998; 94(6):573–578.
   PubMed Web of Science ®Google Scholar
• Neutel J. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 30(101):71S–82S.
   Google Scholar
• Fernández PC, Luque OM, Martell CN, . Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme. Med Clin (Barc) 1993; 101(5):168–171.
   PubMed Web of Science ®Google Scholar
• Hernández R, Armas-Hernández M, Velasco M, Israili Z, Armas-Padilla M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10(6):409–414.
   PubMedGoogle Scholar
• Brook R. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000; 2(4):370–377.
   PubMedGoogle Scholar
• Kasiske B, Ma J, Kalil R, Louis T. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122(2):133–141.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6):499–502.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29(4):270–279.
   PubMed Web of Science ®Google Scholar
• Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens 1993; 6(11):303–308.
   Google Scholar
• Jeppesen J, Hein H, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17(6): 1114–1120.
   PubMed Web of Science ®Google Scholar
• Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59(11):3140–3148.
   PubMed Web of Science ®Google Scholar
• Moan A, Risanger T, Eide I, Kjeldsen S. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3(3):185–188.
   PubMedGoogle Scholar
• Lerch M, Teuscher A, Beissner P, Schneider M, Shaw S, Weidmann P. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31(4):576–580.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Yoshinaga K. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. Blood Press Suppl 1996; 2:78–81.
   PubMedGoogle Scholar
• Cheung R, Lewanczuk R, Rodger N, . The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Prac 1999; 53(8):584–592.
   PubMed Web of Science ®Google Scholar
• Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001; 1:6–11.
   Google Scholar
• Rajagopalan S, Zannad F, Radauceanu A, . Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100(2):222–226.
   PubMed Web of Science ®Google Scholar
• Webster J, Robb O, Jeffers T, Scott A, Petrie J. Once-daily amlodipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1988; 12(7):72–75.
   PubMedGoogle Scholar
• Ahaneku J, Taylor G, Agbedana E, Walker O, Salako L. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. J Pak Med Assoc 1994; 44(7):166–169.
   PubMedGoogle Scholar
• Nandeesha H, Pavithran P, Madanmohan T. Effect of antihypertensive therapy in newly diagnosed essential hypertensive men. Angiology 2009; 60(2):217–220.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bakris GL, Ferrera RD, . Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006; 8(8):571–581.
   Google Scholar
• Preston RA, Harvey P, Herfert O, . A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomittant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47(12):1555–1569.
   PubMed Web of Science ®Google Scholar
• Delsing DJM, Jukema JW, Wiel MAVD, Princen HMG. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3–Leiden transgenic mice. Atherosclerosis 2003; 42(1):63–70.
   Google Scholar
• Andrzejczak D, Gorska D, Czarnecka E. Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep 2006; 58(5):711–719.
   PubMed Web of Science ®Google Scholar